humira_abbott__4

EU approval for Mylan and Fujifilm’s Humira biosimilar

pharmafile | September 21, 2018 | News story | Medical Communications, Sales and Marketing |  EU, Europe, Humira, Mylan, biosimilar, pharma 

The European Commission has approved its fifth biosimilar of the world’s best-selling drug, Abbvie’s Humira (adalimumab), granting marketing authorisation to Mylan and Fujifilm Kyowa Kirin Biologics’ (FFKB) Hulio.

The decision extends across the EU member states and the European Economic Area to all the same indications as its reference product, including rheumatoid arthritis, ulcerative colitis, psoriasis and Crohn’s disease. It follows a positive opinion for the treatment from the Committee for Medicinal Products for Human Use (CHMP) which concluded that Hulio proved adequate biosimilarity to Humira.

Come 16 October, Mylan plans to launch the therapy across European markets, while FKKB holds a nonexclusive royalty bearing license with AbbVie for the sale of Hulio in European countries.

“We’re very pleased with the decision of the European Commission to grant marketing authorisation for Hulio,” Mylan President Rajiv Malik commented. “This is the fourth product that Mylan will be bringing to market in the area of complex generics and biosimilars, and we’re proud to be a leader in the market formation. We’ve made great progress with Fujifilm Kyowa Kirin Biologics and look forward to continuing this important collaboration.”

Advertisement

Dr Yoshifumi Torii, FKKB President and CEO, added: “We are delighted that Hulio has received approval from the European Commission. The EC’s approval of Hulio marks a significant milestone. In cooperating with Mylan, we continue to commit all efforts to bring high quality and affordable biosimilars to patients throughout European countries.”

Matt Fellows

Related Content

Phoenix Labs acquires Kent Pharma

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content